Stocks and Investing
Stocks and Investing
Mon, March 4, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Raghuram Selvaraju Reiterated (BBIO) at Strong Buy and Held Target at $47 on, Mar 4th, 2024
Raghuram Selvaraju of HC Wainwright & Co., Reiterated "BridgeBio Pharma, Inc." (BBIO) at Strong Buy and Held Target at $47 on, Mar 4th, 2024.
Raghuram has made no other calls on BBIO in the last 4 months.
There are 3 other peers that have a rating on BBIO. Out of the 3 peers that are also analyzing BBIO, 1 agrees with Raghuram's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Kostas Biliouris of "BMO Capital" Initiated at Hold and Held Target at $37 on, Wednesday, January 31st, 2024
These are the ratings of the 2 analyists that currently disagree with Raghuram
- David Lebowitz of "Citigroup" Maintained at Strong Buy with Increased Target to $46 on, Friday, February 23rd, 2024
- Josh Schimmer of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $50 on, Monday, January 22nd, 2024
Contributing Sources